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Abstract 
Cardiovascular disease (CVD) has been acknowledged to be a major extra-articular comorbidity in patients with 
rheumatoid arthritis (RA), with myocardial infarction (MI) particularly being the most prominent. Contributory 
factors include the rise in traditional risk factors and proinflammatory changes seen in RA patients. Two drivers 
of proinflammatory changes are mainly emphasized in this review: insulin resistance and dyslipidaemia. Among 
the cytokines involved, tumour necrosis factor alpha (TNF-α) has been identified as one of the major molecules 
contributing to the proatherogenic state seen in these patients. As such, biological therapies such as anti-TNF 
drugs are hypothesized to have a secondary function in reducing CVD in these patients. Using TNF-α as an 
example, this review provides an overview of how chronic inflammation increases the risk of CVD, focusing 
mainly on the two drivers: insulin resistance (IR) state and dyslipidaemia. The review also investigates if anti -
TNF drugs can reduce the effects of these two drivers and hence, determine if anti -TNF drugs can produce a 
clinical effect of reducing the risk of MI in RA patients.  
 
A literature search was conducted using Medline and Google Scholar (1990–January 2013). Studies were selected 
if they addressed the pathophysiology of TNF-α in CVD risk for RA patients or the effects of anti-TNF therapy 
on IR, dyslipidaemia or MI in RA patients. Although the studies were unable to establish if anti-TNF therapy 
can reduce CVD risk, responders to anti-TNF therapy appears to have a significant lower risk of MI.  
 
Despite its effects, additional studies should be conducted to determine its cost-benefit ratio. This is because of 
its high cost and its administration limitations. Future studies should also determine if the lipid profile in RA 
patients truly reflects their risk of CVD, as some studies have reflected an increased CVD risk as compared to 
the general population.  
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Introduction 
 
 
The link between rheumatoid arthritis 
(RA) and cardiovascular disease (CVD) has 
been well established.1,2 It has been 
postulated that since atherosclerosis is in 
part inflammatory, the same inflammatory 
process that drives RA in patients is also 
likely to accelerate the rate of 
atherosclerosis, increasing their risk of CVD. 
It is estimated that 50% of deaths in RA 
patients are caused by CVD, making it the 
largest causative factor in the mortality of 
these patients.3 Studies have shown that 
these patients are more likely to suffer from 
myocardial infarction (MI), as compared to 
stroke.3,4 
 
Over the past 30 years, medical advances in 
chronic inflammation allowed us to have a 
better understanding of the biochemistry 
behind this pathology. This insight has led to 
the development of a promising new class of 
medicine, biologic therapy, now allowing 
doctors to provide a more targeted approach 
in managing patients with chronic 
inflammation. Many cytokines are known to 
drive the inflammatory process, however 
tumour necrosis factor alpha (TNF-α) has 
been touted as one of the main players. 
Given the role of inflammation in 
precipitating atherosclerosis, it is inferred 
that biological drugs such as infliximab 
should have a positive impact on CVD risk, 
and hence the incidence of MI. This has 
prompted many studies to investigate such 
effects, in hopes to significantly improve the 
mortality rates of RA patients.5-11  
 
This paper is particularly useful to medical 
students because, by using the example of 
RA, it will seek to explain why patients with 
chronic inflammation have an increased risk 
of MI, bridging the biochemistry of chronic 
inflammation and the pathophysiology 
behind the rise in CVD risk. In particular, it 
focuses on one main cytokine of 
inflammation, TNF-α. It will also explore 
the role of a new class of biological drugs, 
TNF-α antagonists, and determine if these 
drugs have a potential role in reducing CVD 
risk. One of the challenges in studying if 
TNF-α antagonists can prevent MI is that a 
substantial decrease in CVD risk does not 
necessarily correspond to a decrease in MI. 
Hence, we will conclude by discussing 
whether TNF-α antagonists have a possible 
clinical endpoint of preventing MI and if 
sufficient evidences are present to warrant 
the use of TNF-α antagonist in the 
prevention of MI. We will also look at 
possible gaps in the present knowledge and 
identify potential studies to strengthen the 
present evidence. 
 
Methodology  
 
A literature search was conducted using 
Medline and Google Scholar. Terms used in 
search involved combinations of 
“rheumatoid arthritis”, “myocardial 
infarction”, “anti-TNF/TNF antagonist”, 
“dyslipidaemia”, and “insulin resistance”. 
The results were limited within the period of 
1990–JanuaryD2013. Abstracts from 
potentially relevant literature were vetted 
and only included in the review if they 
addressed the topic. They were also included 
if discussions about the effects of TNA-α 
antagonist on CVD risk were made. 6 
articles were also obtained by conducting a 
manual search on the references in the 
above articles. 
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Rheumatoid Arthritis: An 
Independent Risk Factor 
 
Several studies have shown that patients 
with RA have increased mortality12-14 and 
morbidity rates1,12,15 associated with CVD. In 
particular, a meta-analysis conducted by the 
University of British Columbia and Arthritis 
Research Centre of Canada showed that an 
increase of 50% in CVD-related mortality 
risk was observed for RA patients, versus 
the general population (meta-SMR 1.50, 
95% CI 1.39–1.61).3 Of this, 59% of RA 
patients were more likely to die from MI 
(meta-SMR 1.59, 95% CI 1.46–1.73) while 
52% of them were more likely to die from 
cerebrovascular accidents (CVAs) (meta-
SMR 1.52, 95% CI 1.40–1.67).3 It was also 
noted that the increase in CVD-related 
mortality is not significantly different 
between sexes.  The paper also identified 
that although not all studies included in the 
meta-analysis demonstrated that CVD-
related mortality is higher in RA patients, 
most of these studies had smaller samples. 
As such, lack of persuasive power was a 
plausible reason for not identifying a similar 
pattern in those studies.3 
 
Role of TNF And Anti-TNF Therapy 
in the Pathophysiology of CVD 
 
TNF-α 
In the early 1980s, among the multitude of 
cytokines produced in RA, researchers 
found that TNF-α seemed to be the pivotal 
proinflammatory mediator in the big 
inflammatory cascade.16 Early animal studies 
showed that transgenic mice expressing 
human TNF-α developed an inflammatory 
arthritis similar to RA.17 
 
TNF-α has many effects on the human 
body. However, it can be broadly classified 
into 2 groups: acute effects and chronic 
effects (Figure 1.1).18-20 
 
The biological effects of TNF-α are initiated 
by the ligand-binding of TNF-α and its 
receptors, TNF-RI and TNF-RII.21 These 
receptors are present on the membrane of all 
cell types except erythrocytes.20 While TNF-
RI is the main receptor that establishes the 
effects of TNF-α,22 TNF-RII determines the 
severity of the effects.23 This is because both 
receptors have different intracellular 
signalling pathways and they differ in their 
binding affinity to TNF-α. When stimulated, 
the intracellular domain of TNF-RI binds to 
the TNF receptor associated death domain 
(TRADD) protein.20 TRADD protein 
proceeds to initiate apoptosis via the Fas 
associated death domain (FADD) protein or 
promote inflammation via THNK receptor 
associated factor 2 (TRAF2).20 This activates 
the nuclear factor-κB. In TNF-RII, the 
signalling pathway only allows for the 
promotion of inflammation via the TRAF2 
pathway.20  
 
TNF-α exists in two forms (Figure 1.2): a 
functional membrane protein and a soluble 
protein that is cleaved from the membrane 
by TNF-α converting enzyme.21 Due to the 
significant role that TNF-α plays in RA, new 
biological therapies targeting TNF-α have 
been very efficient in treating RA.24 Some 
studies also suggest that these anti-TNF-α 
drugs have cardioprotective effects for RA 
patients.5,6 They will be discussed in detail 
below. 
 
At present, there are 5 anti-TNF drugs that 
are approved by the United States Food and 
Drug Administration for the treatment of 
RA: infliximab, etanercept, adalimumab, 
golimumab, certolizumab. Table 1.1 
provides a summary of these drugs.25 
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Chronic 
 
TNF-α 
Acute 
1. Propagates inflammatory cascade 
against: 
a. Bacteria 
b. Viruses 
c. Parasites 
2. Increases nutrients uptake for cells  
3. Facilitates a proper host response 
1. Prolongs unnecessary 
inflammation16,17 
2. Promotes atherogenic environment 
3. Favours insulin resistance 
development18,19  
Beneficial for anti-TNF-α therapy? Harmful to use anti-TNF-α 
therapy? 
Figure 1.2. A diagram demonstrating the key proteins involved in extracellular signalling of TNF-α 
and some of the key anti-TNF drugs used in the treatment of RA. TACE-TNF-α converting enzyme; 
sTNF-soluble TNF; proTNF-membrane-bound TNF-α protein. Adapted from McKellar et al, 
2009.21 
 
 
Figure 1.1. A breakdown of the physiological role of TNF-α on the human body. Adapted from Popa 
et al, 2007.20 
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Insulin resistance 
The link between RA and insulin resistance 
(IR) has long been established and it 
correlates with the activity of RA in 
patients.26-28 In a study that consists of 124 
RA patients, it was estimated that the RA 
cohort are 10% more likely to have IR 
compared to the general population.27 A 
similar study by Dessein et al. also yielded 
similar results.28 Several studies attribute 
TNF-α for this phenomenon.18-19 
 
There are several mechanisms to explain 
how TNF-α can induce IR in the body. Its 
effects are mainly seen in adipose tissue 
(Figure 1.3). 
 
Firstly, in vitro studies using murine cell 
cultures have observed that TNF-α is able to 
inhibit the activity of tyrosine kinase found 
on insulin receptors. This was possible due 
to serine phosphorylation of insulin receptor 
substrate 1 (IRS-1), converting it to an 
inhibitor of tyrosine kinase. This would 
effectively inhibit the insulin receptor 
intracellularly, rendering it useless even when 
the insulin molecules bind to its receptor. 
This effect is initiated by the activation of 
TNF-RI.29  
 
Secondly, the rise in TNF-α levels also 
stimulates an increase in the levels of free 
fatty acid (FFA). This results from the rise in 
the rate of lipolysis from adipose tissue.30 
Stimulation of gluconeogenesis in hepatic 
cells and a decrease in the rate of glucose 
uptake and metabolism would follows in 
skeletal muscle cells. The end result would 
help contribute to an insulin-resistant state.20 
 
Thirdly, TNF-α has been known to 
downregulate the expression of some 
proteins in adipocytes. These include 
glucose transporter type 4 (GLUT-4), IRS-1, 
peroxisome proliferator-activated receptor 
gamma (PPAR-γ) and adiponectin.31-33 A 
reduction in insulin-sensitive GLUT-4 
indicates that the rate of glucose uptake in 
adipose tissue would be reduced, causing a 
rise in blood glucose level. Also, 
adiponectin, a protein hormone that 
modulates insulin sensitivity, has an inverse 
relationship with the overall systemic insulin 
resistance.34 Hence, the overall increase in 
insulin resistance could increase the CVD 
risk of RA patients. 
 
Lastly, proinflammatory proteins such as 
leptins and monocyte chemoattractant 
protein-1 (MCP-1) have been observed to be 
upregulated in patients with elevated TNF-α. 
It is believed that these proteins further 
worsen the degree of insulin resistance.34,35 
However, the pathogenesis has yet to be 
fully established. 
 
Effects of anti-TNF therapy on IR 
 
In many studies, the homeostatic model 
assessment index36 (HOMA) calculation was 
used to quantify the level of IR while the 
quantitative insulin sensitivity check index37 
(QUICKI) measures the level of insulin 
sensitivity. As such, these measures will be 
used below to discuss about the effects of 
anti-TNF therapy on IR. 
 
A study conducted using infliximab on 45 
patients with either RA or ankylosing 
spondylitis has shown some benefits on the 
level of IR.38 Although it was observed that 
there were no significant changes of the 
HOMA and QUICKI in the whole study, 
patients with the highest IR (n=14) showed 
significant improvement in HOMA and 
QUICKI. This translates that the level of IR 
in these patients was reduced while the 
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insulin sensitivity improved.38 Another study 
involving 10 patients also showed that 
infliximab does not result in an overall 
significant improvement of HOMA and 
QUICKI.39 In that study, however, a 
separate analysis on the highest IR subjects 
were not conducted due to the small cohort 
size. Other studies involving diabetic 
patients who have IR also failed to show the 
hypothetical beneficial effects of anti-TNF 
therapy.40,41 
 
Dyslipidaemia 
Based on the ATP III classification, 
dyslipidaemia is defined as a state of high 
low-density lipoprotein (LDL), high total 
cholesterol (Tchol) and low high-density 
lipoprotein (HDL) levels. It has been well 
established that this state can greatly increase 
the risk of CVD.42 Hence, we will focus on 
these three types of cholesterol in this 
discussion.  
 
Dyslipidaemia appears to be elevated in the 
RA cohort. However, the evidence seems 
conflicting. Several studies found that RA 
patients tend to have highly atherogenic 
dyslipidemic patterns, as compared to their 
age and gender matched controls.43,44 
However, in another population-based case 
control study, an opposite effect was seen. It 
was observed that RA patients have lower 
Tchol and LDL levels as compared to the 
control cohort. The study also found that 
the LDL levels in the RA cohort were 
reduced significantly 5 years before the 
diagnosis of RA.45 Hence, it appears that RA 
seems to create an antiatherogenic lipid 
profile in patients. However, a population 
based study of RA in 2011 showed that such 
antiatherogenic lipid profile in RA patients 
can paradoxically increase the risk of CVD.46 
This phenomenon will be further elaborated 
below. 
 
Patients with a high RA activity also tend to 
have lower HDL levels.47-49 There are also 
studies that suggest HDL, an established 
cardioprotective marker, could be modified 
into a proinflammatory product, accelerating 
the progression of atherosclerosis.50,51 As 
such, it is widely agreed that systemic 
inflammation can alter the lipid profile in 
human body.52-54 Studies have suggested that 
the interference of TNF-α in cholesterol 
metabolism and the reverse cholesterol 
transport are the main reasons why the lipid 
profiles in these patients are highly 
proatherogenic.20 
 
Cholesterol Metabolism 
 
Cell lines using human hepatoma cells 
showed that TNF-α decreases the secretion 
of apolipoprotein A and B (apo-A and apo-
B).55 As these proteins are necessary to form 
lipoproteins, their reduced expression will 
decrease levels of HDL and LDL found in 
the circulatory system (Figure 1.4).55 
 
CYP7A1 is an enzyme that helps eliminate 
cholesterol by converting it to become bile 
acid. This enzyme is found to be the rate-
limiting step in the classical pathway of bile 
acid formation. Studies have found that in 
times of inflammation, cytokines such as 
TNF-α are able to reduce the activity of 
CYP7A1.56 In addition, downregulating the 
activities of mitochondrial sterol 27-
hydroxylase and oxysterol 7α-hydroxylase 
further dampens the synthesis of bile acid 
via the alternative pathway.57 Although it is 
not known if this alteration helps promote a 
proatherogenic state in RA patients, it 
redirects available cholesterols for other 
hepatic processes in times of inflammation.56 
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In vitro studies also showed that TNF-α 
promotes the clearance of LDL from the 
circulatory system.52 This could explain the 
reduction of LDL levels found in patients 
with RA. This is achieved by promoting the 
synthesis of LDL receptor on hepatocytes, 
allowing an increase in uptake of LDL.52 
Such mechanisms appear to look 
antiatherogenic.  
 
However, as mentioned previously, these 
antiatherogenic profiles increase the risk of 
CVD in RA patients. This is because TNF-α 
stimulates changes in the composition of 
LDL, making it more atherogenic. Patients 
with elevated TNF-α were found to have a 
higher concentration of oxidized LDL in 
their circulation as TNF-α increases the 
expression of secretory phospholipase A2 in 
LDL, hence increasing the hydrolysis of 
phospholipids. This would generate higher 
levels of fatty acids that would eventually 
result to an increase in oxidized LDL.58 It 
was also noted that TNF-α could stimulate 
hepatic sphingolipid synthesis, significantly 
altering the structure of circulating 
lipoprotein to make them more 
atherogenic.53 
 
Reverse Cholesterol Transport 
 
Reverse cholesterol transport is a widely 
accepted hypothesis that explains the role of 
HDL in removing excess cholesterol from 
the circulation and transferring them to the 
liver for excretion. Impairment to this 
mechanism is known to promote 
atherosclerosis, and many believe that the 
interference of TNF-α explains the increased 
risk of CVD in RA patients (Figure 1.5).20,59-
61 
 
Studies conducted in primates have 
suggested that TNF-α decreases the 
synthesis and activity of lecithin cholesterol 
acyltransferase (LCAT).59 This is an 
important enzyme that catalyses the 
conversion of free cholesterol into 
cholesteryl ester, an essential molecule for 
the formation of HDL. A decrease in LCAT 
would result in a decrease in HDL 
concentration, and this could account for 
the drop in cholesterol concentration after a 
TNF-α infusion.54 
 
TNF-α is also known to impair the uptake 
and excretion by hepatocytes by 
downregulating the expression of scavenger 
receptor class B.60 This receptor is known to 
bind oxdized LDL, normal LDL and HDL, 
promoting the catabolism of these 
molecules.62-65 It is believed that during 
acute-phase inflammation, the reduced 
uptake of these molecules would help direct 
cholesterols towards inflammatory cells, 
such as macrophages, to aid in host 
defences. However, a prolonged 
inflammatory process would encourage 
deposition of cholesterol in macrophages, 
contributing to the formation of 
atherosclerotic plaques.60 
 
Elevated levels of TNF-α have been 
observed to modify the structure of HDL. 
Compounds such as apoJ and 
apolipoprotein serum amyloid A (apoSAA) 
were elevated while others such as 
apolipoprotein A-I (apoA-I) and 
paraoxonase-1 (PON1) were decreased.61,66 
This is important because apoA-I is greatly 
associated to the ability of a type of HDL, 
pre-β HDL, in attracting cholesterol from 
the circulation. As such, the protective 
effects of HDL are significantly decreased in 
these patients. PON-1 is a major 
antiatherogenic molecule in HDL because it 
promotes antioxidant properties in HDL. 
This allows HDL to protect LDL and itself 
from oxidation, preventing them from 
becoming proatherogenic molecules.67 
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Types of anti-TNF Structure 
Infliximab A chimeric, monoclonal IgG1 antibody. It is made of 75% human 
and 25% murine. 
Etanercept A recombinant human TNF dimeric fusion protein receptor. 
Combination of extracellular domain of p75 TNF receptor and the 
Fc domains of human IgG1 antibody. 
Adalimumab  Full human monoclonal antibody, indistinguishable from the 
naturally occurring IgG1 in the human body. 
Golimumab A human monocloncal IgG1 antibody. Similar to Adalimumab. 
Certolizumab An antibody that is made up of Fab fragment of humanised TNF, 
combined with polyethylene glycol. 
Table 1.1. A summary of the structures of different anti-TNF drugs.25 
 
Figure 1.3. A diagram illustrating the possible mechanisms of TNF-α on IR. Adapted from Popa et 
al, 2007.20 
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Based on the studies shown above, the rise 
in TNF-α levels could induce a 
hypocholesterolaemia state in RA patients. 
However, the effects of TNF-α on 
lipoproteins make these patients highly 
atherogenic. In view of the positive 
correlation between RA and CVD, it would 
appear that the increased atherogenic effect 
of the lipoprotein surpasses the 
cardioprotective effects of a 
hypocholesterolaemia state. However, 
further studies will be required to confirm 
this hypothesis. 
 
Effects of Anti-TNF Therapy on 
Dyslipidaemia  
 
Several studies looking at the effects of anti-
TNF therapy on the lipid profile of patients 
have been conducted. A summary can be 
seen in Table 1.2. 
 
It appears that the effects of anti-TNF on 
the lipid profile are rather complicated. 
Although the studies did not yield identical 
results, there were some similarities. In 
general, anti-TNF therapies appear to 
elevate the total cholesterol and HDL levels. 
Some of these studies noted that the effects 
were still sustained after 6 weeks of 
therapy.49 Even so, no improvements in the 
atherogenic index were seen, given the rise 
in levels of protective HDL. The only 
exception was in a study where adalimumab 
was used.68 
 
Clinical End-Point: Myocardial 
Infarction 
 
Based on the effects of TNF-α on reducing 
the clearance rate of cholesterol in the body 
and making lipoproteins more reactive to 
oxidation, one would assume that the use of 
anti-TNF therapy will, in theory, reduce the 
rate of plaque formation and hence the 
incidences of MI in RA patients. However, 
this direct correlation has yet to been seen.  
 
Data obtained from the British Society for 
Rheumatology Biologics Register (BSRBR) 
has shown some encouraging results.5 The 
cohort study concluded that when compared 
to patients using the traditional disease-
modifying antirheumatic drugs (DMARDs), 
anti-TNF therapy does not reduce the risk 
of MI (incidence rate 1.44, 95% CI 0.56–
3.67). However, further analysis of the data 
observed that responders to anti-TNF 
therapy had a significant reduction in the 
incidence rate of MI as compared to non-
responders (incidence rate 0.36, 95% CI 
0.19–0.69). Due to the nature of the study, 
the risk of bias was low. Coupled with such 
hopeful results, it appears that anti-TNF 
therapy could in fact reduce the risk of MI in 
RA patients that respond to these 
treatments.5 
 
A cross sectional study using data collected 
from the QUEST-RA study further 
indicated that the prolonged exposure to 
anti-TNF drugs could reduce MI by 58% as 
compared to RA patients with no DMARDs 
(HR 0.42, 95% CI 0.21–0.81).6 This was 
observed to be even better than the 
improvement seen in methotrexate 
treatment (HR 0.85, 95% CI 0.81–0.89). 
However, 4 other case-control studies 
showed differing outcomes. They observed 
that there was no significant decrease in the 
risk of MI when comparing anti-TNF 
therapy (monotherapy or combined 
therapy)7-10 with no DMARDs. No 
segregation between responders and non-
responders was conducted in these studies. 
As such, the possibility of non-responders 
skewing the results in these studies must be 
considered.  
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Further studies looking at the combined 
effects of anti-TNF therapy with other 
DMARDs were also conducted.11 Although 
the monotherapy of anti-TNF did not 
reduce the rate of MI (RR 1.17, 95% CI 
0.50–2.75), the combined therapy of 
methotrexate with anti-TNF was seen to be 
superior in reducing the risk of MI as 
compared to methotrexate monotherapy. An 
80% reduction of risk was obtained (RR 0.8, 
95% CI 0.05–0.88).11 
 
Discussion 
Present studies conducted do support the 
idea that TNF-α is a major contributor to 
the increased risk of CVD. However, the 
association between anti-TNF therapy and 
its benefits on IR and dyslipidaemia remains 
unestablished. 
 
Many studies38-41 have already indicated that 
anti-TNF therapy does not significantly 
improve the IR status seen in RA patients. 
However, one study by Kiortsis et al. noted 
significant improvement in the IR with 
patients having the highest IR.38 As other 
studies mentioned did not perform a 
separate analysis on patients with the highest 
IR, it is difficult to determine if anti-TNF 
therapy does produce significant benefit to 
only patients with the highest IR. As such, 
future studies looking at patients with the 
highest IR will be necessary before one can 
definitively conclude the lack of 
effectiveness of anti-TNF therapy on IR.  
 
The effects of anti-TNF therapy on 
dyslipidaemia however, appears to be more 
promising. Evidence presented has indicated 
similar results, showing that anti-TNF 
therapy increases the Tchol and HDL in RA 
patients.5,47,49 However, as the cardio-
protective effects provided from HDL in the 
RA population appears to be less than the 
general population, a rise in HDL after anti-
TNF therapy cannot definitively indicate a 
reduction in CVD risk. Future studies will 
first be required to establish if the lipid 
profile levels of the RA population truly 
reflects the same level of CVD risk in the 
general population. A longer-term study will 
also be required to determine if these 
improved lipid profile levels are sustainable 
in the long run.  
 
Studies looking at the effects of anti-TNF 
therapy in the prevention of MI indicated 
that it may be effective in the prevention of 
the disease for responders of the treatment. 
Results from the BSRBR, one of the largest 
observational study conducted to date, 
brought forth an interesting point: although 
the overall risk of MI was not reduced, when 
compared to the control cohort that used 
DMARDS, there was a significant reduction 
in the events of MI when comparing 
responders and non-responders to anti-TNF 
therapy.5 This study may indicate that anti-
TNF therapy only prevents MI in a 
particular group of patients. However, it may 
also show that the reduction of MI is 
attributed to a more well controlled RA 
disease. A comparison study looking at 
responders to DMARDS and anti-TNF 
therapy would be useful as it can better 
attribute the prevention of MI to the drugs 
used, instead of the level of inflammation. 
Future studies should also focus mainly on 
responders to anti-TNF therapy as this 
would prevent the non-responders from 
skewing the results, as seen in this study.   
 
One of the main limitations in this review is 
the use of mainly infliximab in studies of 
anti-TNF therapy.  As infliximab was the 
first anti-TNF drug to be marketed, it has 
the greatest number of published studies  
carried out to determine its effects.  
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Study Cohort size Treatment regime Effects on lipid profile  
Allanore et al. RA patients  
n=56 
Infliximab (3mg/kg)   
weeks:0,2,6,14,22,30 
Total Chol ↑, LDL↑, HDL↑, 
Triglyceride ↔, Total 
Chol/HDL↔, LDL/HDL ↔  
Vis et al. RA patients 
n=69 
Infliximab (3mg/kg) 
weeks:0,2,6 
Total Chol ↑,HDL↑, Total 
Chol/HDL↔ 
Popa et al. RA patients 
n=33 
Adalimumab, 
weeks:0,2 
HDL↑, LDL↔, 
Triglyceride↔, Total 
Chol/HDL↓ 
Peters et al. RA patients 
n=80 
Infliximab (3mg/kg) 
Weeks 0,2,6 and 
every 8 weeks after 
Total Chol ↑, HDL↑, 
Triglyceride↑, Total 
chol/HDL↓ 
 
Popa et al. RA patients  
n=67 
Inflximab (3mg/kg) 
weeks: 0,2,6 nad 
every 8 weeks after 
Total Chol ↑, LDL↑, HDL↑, 
Triglyceride ↔, Total 
Chol/HDL↔, LDL/HDL ↔  
 
 
 
Hypocholesterolemia State Pro-atherogenic state 
Figure 1.4. A summary of the mechanisms of TNF-α affecting cholesterol metabolism. Adapted from 
Popa et al, 2007.20 
 
Figure 1.5. A summary of the mechanisms of TNF-α affecting reverse cholesterol transport. 59-61 
 
 
Table 1.2. A table of the summary of studies conducted on the effect of anti-TNF therapy on lipid 
profile. Adapted from McKellar et al, 2009.21 
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As such, there is a high risk of bias that the 
effects of infliximab may not be a true 
reflection of other anti-TNF therapy. This 
review also focuses on only RA and thus, its 
results cannot be generalized to other types 
of inflammatory rheumatic disorder. 
Another source of limitation is the lack of 
statistical techniques to collectively conclude 
the results from the studies used. Future 
reviews can use a wider range of anti-TNF 
drugs and other types of inflammatory 
rheumatic disorder when such information 
are more readily available. A systemic review 
can also be conducted to provide a stronger 
case for the use of anti-TNF therapy in the 
prevention of MI. 
 
In view of its potential role in the prevention 
of MI, clinical implications of the use of 
anti-TNF therapy must also be considered. 
With the drug costing about GBP 13,000 per 
year per patient69 and the need to administer 
the drug via intravenous infusion every 6 to 
8 weeks,69 it may be impractical at present to 
administer such drugs to prevent MI. 
However, future studies should still weigh 
the cost-benefit ratio of this therapy as such 
studies may motivate pharmaceutical 
companies to discover alternative routes to 
deliver this drug. Possible side effects of the 
medication should also be further 
monitored. A randomized controlled trial 
conducted in 2003 noted that when used in 
high doses, infliximab adversely worsened 
the conditions of patients with moderate to 
severe chronic heart failure.70 However, the 
association has yet to be firmly established. 
 
 
 
 
 
Conclusion 
 
In summary, although it remains 
controversial if anti-TNF therapy improves 
the IR and dyslipidaemia state in RA 
patients, there are indications that 
responders to anti-TNF therapy may benefit 
in the prevention of MI. Further studies 
targeting this group should be initiated and a 
wider range of anti-TNF drugs can be 
investigated. 
 
 
Key Learning Points 
 TNF-α plays a pivotal role in the 
inflammatory process. 
 
 TNF-α increases CVD risk in RA 
patients by promoting dyslipidaemia and 
insulin resistance. 
 
 Although the overall risk of MI is not 
reduced, responders to anti-TNF therapy 
displayed a significant reduction in risk of 
MI.  
 
 There is some evidence to support the 
secondary role of anti-TNF therapy in the 
reduction of MI risk in RA patients, 
however, more studies are necessary to 
cement the findings. 
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